Researchers advance in utero CRISPR gene editing for rare diseases

The short version

• CNBC reports that researchers including Kiran Musunuru and William Peranteau are developing CRISPR gene editing to treat genetic diseases before birth.[CNBC]
• Early animal tests showed CRISPR tools can reach the heart and hard-to-reach muscles of unborn animals, a potential route for conditions such as Duchenne muscular dystrophy.[CNBC]
• Human trials are at least three years away, and researchers warn against creating false hope. Neurological conditions remain out of reach because of the blood-brain barrier.[CNBC]

Key facts

• Kiran Musunuru of the University of Pennsylvania said that to prevent the worst effects of disease, treatment must happen in utero.[CNBC]
• Musunuru helped develop the world's first personalized gene editing treatment for an infant with a rare genetic disorder in 2025.[CNBC]
• Musunuru and William Peranteau found that CRISPR delivery tools can reach the heart and hard-to-reach muscles of unborn animals.[CNBC]
• The researchers are at least three years away from trying fetal gene editing in humans.[CNBC]
• Getting past the blood-brain barrier remains difficult, so neurological conditions are currently out of reach for fetal gene editing.[CNBC]
• David Stitelman of Yale School of Medicine said improving diagnostic technology makes fetal diagnosis seem less far-fetched than it once did.[CNBC]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.

• Could CRISPR cure rare diseases before birth? Scientists are getting closerCNBC